Use of the Limulus amebocyte lysate test as a cost-effective screen for gram-negative agents of meningitis. 1987

M A Saubolle, and J H Jorgensen
Department of Pathology, Good Samaritan Medical Center, Phoenix, AZ 85006.

A retrospective review of data from two institutions demonstrated that the Limulus amebocyte lysate test was a simple and cost-effective means to screen cerebrospinal fluids (CSF) for Gram-negative agents of meningitis. Results of either gelation Limulus amebocyte lysate (LAL) or chromogenic Limulus amebocyte lysate (CLAL) tests on 1504 CSF were evaluated along with results of antigen detection tests [ADT; either latex agglutination (LA) or counterimmunoelectrophoresis (CIE)], cultures, and Gram-stains. All 127 CSF positive for Haemophilus or Neisseria by culture and/or ADT were also positive by Limulus test (100%). The sensitivities of Gram stain examination, culture, LA, and CIE for these two pathogens were 81%, 91%, 86%, and 63%, respectively. The Limulus test on lumbar CSF was positive in 67% of cases with other Gram-negative bacillary meningitis, in 33% of cases with Gram-negative bacillary abscess or ventriculitis, in none of the cases with Gram-positive, mycobacterial, treponemal, fungal, or viral meningitis, and in 1% of cases with either normal or otherwise negative bacteriologic findings. Overall, sensitivity and specificity of the Limulus test were 97% and 99%, respectively. The cost of either version of the Limulus test was less than 15% of the cost of ADT batteries for Haemophilus and Neisseria. Based on its sensitivity for Haemophilus and Neisseria in CSF, we propose its use as a cost-effective screen to minimize the need for the more expensive ADT batteries.

UI MeSH Term Description Entries
D007841 Latex Fixation Tests Passive agglutination tests in which antigen is adsorbed onto latex particles which then clump in the presence of antibody specific for the adsorbed antigen. (From Stedman, 26th ed) Latex Agglutination Tests,Agglutination Test, Latex,Agglutination Tests, Latex,Fixation Test, Latex,Fixation Tests, Latex,Latex Agglutination Test,Latex Fixation Test,Test, Latex Agglutination,Test, Latex Fixation,Tests, Latex Agglutination,Tests, Latex Fixation
D008033 Limulus Test Sensitive method for detection of bacterial endotoxins and endotoxin-like substances that depends on the in vitro gelation of Limulus amebocyte lysate (LAL), prepared from the circulating blood (amebocytes) of the horseshoe crab, by the endotoxin or related compound. Used for detection of endotoxin in body fluids and parenteral pharmaceuticals. Limulus Tests,Test, Limulus,Tests, Limulus
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008583 Meningitis, Haemophilus Infections of the nervous system caused by bacteria of the genus HAEMOPHILUS, and marked by prominent inflammation of the MENINGES. HAEMOPHILUS INFLUENZAE TYPE B is the most common causative organism. The condition primarily affects children under 6 years of age but may occur in adults. Haemophilus influenzae Meningitis Type B,Hemophilus influenzae Meningitis Type B,Meningitis, Haemophilus influenzae Type F,Meningitis, Haemophilus parainfluenzae,Meningitis, Hemophilus,Meningitis, Hemophilus influenzae Type F,Meningitis, Hemophilus influenzae, Type B,Meninigitis, HiB,Type B Haemophilus influenzae Meningitis,Type B Hemophilus influenzae Meningitis,Haemophilus Meningitides,Haemophilus Meningitis,Haemophilus parainfluenzae Meningitides,Haemophilus parainfluenzae Meningitis,Hemophilus Meningitides,Hemophilus Meningitis,HiB Meninigitis,Meningitides, Haemophilus,Meningitides, Haemophilus parainfluenzae,Meningitides, Hemophilus
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D003378 Counterimmunoelectrophoresis Immunoelectrophoresis in which immunoprecipitation occurs when antigen at the cathode is caused to migrate in an electric field through a suitable medium of diffusion against a stream of antibody migrating from the anode as a result of endosmotic flow. Electrosyneresis,Immunoelectroosmophoresis,Immunoelectrophoresis, Countercurrent,Immunoelectrophoresis, Crossover,Countercurrent Immunoelectrophoresis,Crossover Immunoelectrophoresis
D004731 Endotoxins Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. Endotoxin
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria

Related Publications

M A Saubolle, and J H Jorgensen
July 1976, Pediatrics,
M A Saubolle, and J H Jorgensen
November 1973, The New England journal of medicine,
M A Saubolle, and J H Jorgensen
December 1976, American journal of clinical pathology,
M A Saubolle, and J H Jorgensen
January 1973, Bulletin of the Parenteral Drug Association,
M A Saubolle, and J H Jorgensen
June 1974, Quaderni Sclavo di diagnostica clinica e di laboratorio,
M A Saubolle, and J H Jorgensen
September 1975, The Journal of laboratory and clinical medicine,
M A Saubolle, and J H Jorgensen
January 1987, Progress in clinical and biological research,
M A Saubolle, and J H Jorgensen
January 1991, Journal of parenteral science and technology : a publication of the Parenteral Drug Association,
M A Saubolle, and J H Jorgensen
January 1985, Progress in clinical and biological research,
Copied contents to your clipboard!